Digital Health Companies: How to choose a business model to bring your consumer-centric care to the market

Meet the Women of NGL: International Women's Day 2022

For International Women’s Day 2022, and especially the global theme of #BreaktheBias, we have two treats for novel and disruptive healthcare and life sciences innovators.

2022 Trends and Opportunities for Healthcare and Life Sciences Businesses and Investors

Find out what Healthcare and Life Sciences businesses and investors anticipate for the healthcare industry in 2022.

Pharmacy Innovation Series: the DEA Steps into Telepharmacy Regulation

For the first time, the Drug Enforcement Agency (“DEA”) is becoming directly involved in the telepharmacy space, an industry that the DEA has not previously regulated aside from the loose application of its existing regulations governing online pharmacies. Find out what this means for your business and how you can submit comments to the DEA directly in this post.

Everything you need to know about the 2022 MPFS Proposed Rule

Digital Health, Life Sciences, Physician Fee Schedule, Medicare, Reimbursement, Remote Patient Monitoring, Telehealth, TelemedicineNixon Gwilt LawAugust 9, 2021MPFS, proposed rule, virtual care, rpm, Remote Therapeutic Monitoring, Chronic Care Management, Telehealth, CMS, 2022 Medicare Physician Fee Schedule

Can Biotech and Pharma Companies pay contracted sales teams a commission-based fee?

The U.S. Department of Justice (DOJ) just sent a strong message to pharmaceutical and biotechnology companies who rely on contracted sales teams to push their products into the market: “commission-based compensation violates the Federal Anti-Kickback Statute (AKS)”.

This message seems to undermine years’ worth of relative stability in how these companies evaluate risks associated with commission-based compensation that does not fit squarely into a legal safe harbor under the AKS.

Life Sciences, LegislationTommy MillerJuly 1, 2021biotech, pharma, sales, fraud, aks